1428523-46-9

Upstream product

• 1227187-59-8 trans-4-(isopropoxy)cyclohexanecarboxylic acid ethyl ester 
• 1227187-86-1 trans-4-(isopropoxy)cyclohexanecarboxylic acid hydrazide 
• 1428523-61-8 7-chloro-3,5-dihydrobenzo[e][1,4]oxazepine-2(1H)-thione 
• 37585-25-4 2-amino-5-chlorobenzyl alcohol 
• 1428523-59-4 2-bromo-N-(4-chloro-2-(hydroxymethyl)phenyl)acetamide 
• 1428523-60-7 7-chloro-3,5-dihydrobenzo[e][1,4]oxazepin-2(1H)-one 

Relevant academic research and scientific papers

OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS

The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes of the formula wherein R1 and R2 are as defined herein and which act as V1a receptor modulators, and in particular as V1a receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments.

OXY-CYCLOHEXYL-4H,6H-5-OXA-2,3,10B-TRIAZA-BENZO[E]AZULENES AS V1A ANTAGONISTS

The present invention provides 4H,6H-5-oxa-2,3,10b-triaza-benzo[e]azulenes, which act as V1a receptor modulators, and in particular as Via receptor antagonists, their manufacture, pharmaceutical compositions containing them and their use as medicaments. The active compounds of the present invention are useful as therapeutics acting peripherally and centrally in the conditions of dysmenorrhea, male or female sexual dysfunction, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, anxiety, depressive disorders, obsessive compulsive disorder, autistic spectrum disorders, schizophrenia, and aggressive behavior.